Companion Diagnostics Market

Companion Diagnostics Market by Product (Assays, Kits, Software & Services), Technology (PCR, NGS, ISH, IHC), Indication (Breast, Blood, Lung, Colorectal Cancer, Neurology Diseases), End User (Pharma Companies, CROs) & Region - Global Forecast to 2026

Report Code: MD 5463 Feb, 2022, by marketsandmarkets.com

Updated on : May 04, 2023

The global companion diagnostics market in terms of revenue was estimated to be worth $5.5 billion in 2021 and is poised to reach $9.9 billion by 2026, growing at a CAGR of 12.6% from 2021 to 2026. The new research study consists of an industry trend analysis of the market. The new research study consists of industry trends, pricing analysis, patent analysis, conference and webinar materials, key stakeholders, and buying behaviour in the market. Market growth is driven by factors such as the growing significance of companion diagnostics in drug development and rising incidence of cancer and growing adoption of targeted therapies.

Companion Diagnostics Market

To know about the assumptions considered for the study, Request for Free Sample Report

Companion Diagnostics Market Dynamics

Driver: Growing need for targeted medicines

With advances in genetic sequencing and genomics, it is now widely believed that drugs can show varying outcomes in different individuals. A better understanding of the genetic characteristics or biomarkers of an individual can promote the practice of administering ‘the right drug, at the right time, at the right dose, for the right person’. Pharmaceutical and biopharmaceutical companies are continuously attempting to implement patient-selection diagnostic frameworks in the earlier stages of drug development to provide targeted therapies to the right candidate. This further supports the growth of the market.

Opportunity: Increasing demand for next-generation sequencing

NGS-based companion diagnostic tests aim to unlock molecular information from each patient's tumor genome to guide treatment decisions for cancer therapies. Next-generation sequencing detects multiple biomarkers for multiple drug therapies in a shorter time frame as compared to other sequencing techniques. The use of NGS panels for biomarker measurement in one test has the potential to help in the treatment of many different types of cancers. The various technological advancements in NGS also provide market players with an immediate competitive edge over players providing other technologies such as PCR, ICH, and ISH. As a result, major market players are focusing on developing companion diagnostic products based on NGS.

Restraint: High cost of immunotherapy treatment

While immunotherapy has shown significant promise in cancer treatment, its high cost has limited overall patient access. Physicians might instead find it best to combine therapies; this, in turn, might extend the duration of the treatment from five months to over three years. In this case, the longer the duration, the greater the expense. In addition, the cost of personalized immunotherapies is high. For example, KYMRIAH, the approved CAR T-cell treatment from Novartis, and YESCARTA, from Gilead Sciences, costs between USD 373,000 and USD 475,000 per patient, depending on the type of cancer being treated. Each CAR T-cell treatment is designed specifically for the patient, utilizing substantial lab resources. Thus, the cost for just the drug goes up to about USD 60,000 per patient. The cost of cancer immunotherapies can far exceed the cost required for other therapy options, such as chemotherapy or radiation therapy. Thus, the high cost of immuno-oncology therapies is expected to hamper the growth of market.

Challenge: Lack of awareness of companion diagnostics testing

It is important to build awareness amongst patients, clinicians, and the public regarding the importance of clinical trials. To improve awareness among clinicians, providing special access to reputable, evidence-based latest information on these new cancer medicines can be helpful. To improve public awareness, increasing access to a common and trusted source of truth is necessary. Several publishing houses and industry players provide monthly journals and information leaflets. Stakeholders have also focused on awareness initiatives to ensure patients and providers can access and understand the benefits of companion diagnostics.

The market is highly consolidated. The top players—F. Hoffmann-La Roche Ltd. (Switzerland), Agilent Technologies, Inc. (US), Qiagen N.V. (Germany), Thermo Fisher Scientific, Inc. (US), Abbott Laboratories, Inc. (US) -in the market accounted for a combined majority market share in 2020. There is a high degree of competition among the market players. Only major companies can afford high-capital investments as well as the high cost of R&D and manufacturing. This will prevent new entrants from entering this market.

Assays, kits & reagents segment accounted for the largest share of the companion diagnostics market, by product & service

The market is segmented into assays, kits & reagents, and software & services. The assays, kits & reagents accounted for the largest share of the market, mainly due to the the availability of a wide range of products, and increasing use of assays and kits in different therapeutic areas.

PCR segment accounted for the largest share in the companion diagnostics market, by technology.

The market is segmented into polymerase chain reaction (PCR), next-generation sequencing (NGS), in situ hybridization (ISH), immunohistochemistry (IHC), and other technologies. The PCR segment accounted for the largest share of the market. Factors such as the ease of use and widespread availability of PCR kits & reagents in companion diagnostic testing, and growing applications of PCR in the high-throughput detection of mutants with a limited or low allele frequency of genes.

Cancer segment accounted for the largest share in the companion diagnostics market, by indication.

The market is segmented into cancer, cardiovascular diseases (CVDs), neurological diseases, infectious diseases, and other indications (inflammatory and inherited diseases, among others). The cancer segment accounted for the largest share of the market. Factors such as growing role of companion diagnostics in the personalized medicine treatment for cancer, and increasing utility of biomarkers in the diagnosis of cancer.

Pharmaceutical & biotechnology companies and reference laboratories segment accounted for the largest share in the companion diagnostics market, by end user.

The market is segmented into pharmaceutical & biotechnology companies, reference laboratories, CROs, and other end users (including physician & hospital laboratories, and academic medical centers). Pharmaceutical & biotechnology companies accounted for a larger share of the market. The growing use of companion diagnostics owing to their increasing prominence in drug development, and the increasing importance of companion diagnostic biomarkers.

North America is accounted the largest region of companion diagnostics market.

The global market is segmented into five major regions—North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. North America accounted for the largest share of the market. The North American market growth can be attributed to the presence of many leading companion diagnostics vendors & national clinical laboratories, the easy accessibility to technologically advanced devices and instruments, and the highly developed healthcare system in the US and Canada.

To know about the assumptions considered for the study, download the pdf brochure

Companion Diagnostics Market Report Scope

Report Metric

Details

Market Revenue in 2021

$5.5 billion

Projected Revenue by 2026

$9.9 billion

Revenue Rate

Poised to grow at a CAGR of 12.6%

Market Driver

Growing need for targeted medicines

Market Opportunity

Increasing demand for next-generation sequencing

This study categorizes the global companion diagnostics market to forecast revenue and analyze trends in each of the following submarkets:

By Product & Service

  • Assays, Kits & Reagents
  • Software & Services

By Technology

  • Polymerase Chain Reaction
  • Next-generation Sequencing
  • In Situ Hybridization
  • Immunohistochemistry
  • Other Technologies

By Indication

  • Cancer `
    • Lung Cancer
    • Breast Cancer
    • Blood Cancer
    • Colorectal Cancer
    • Other Cancer Types
  • Neurological Disorders
  • Cardiovascular Diseases
  • Infectious Diseases
  • Other Indications

By End User

  • Pharmaceutical & Biopharmaceutical Companies
  • Reference Laboratories
  • Contract Research Organizations
  • Other End Users

By Region

  • North America
    • US
    • Canada
  • Europe
    • Germany
    • UK
    • Switzerland
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • Australia
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa

Recent Developments

  • In May 2021, Qiagen N.V. (Germany) expanded the therascreen KRAS Kit.
  • In April 2019, Roche Diagnostics (Switzerland) acquired TIB Molbiol Group (Germany). This acquisition will enhance Roche’s broad portfolio of molecular diagnostics solutions with a wide range of assays for infectious diseases, such as identifying SARS-CoV-2 variants.

Frequently Asked Questions (FAQ):

To speak to our analyst for a discussion on the above findings, click Speak to Analyst

TABLE OF CONTENTS

1 INTRODUCTION (Page No. - 28)
    1.1 OBJECTIVES OF THE STUDY
    1.2 MARKET DEFINITION
           1.2.1 INCLUSIONS & EXCLUSIONS OF THE STUDY
    1.3 MARKETS COVERED
           FIGURE 1 COMPANION DIAGNOSTICS MARKET SEGMENTATION
           1.3.1 YEARS CONSIDERED FOR THE STUDY
    1.4 CURRENCY
    1.5 LIMITATIONS
    1.6 STAKEHOLDERS
    1.7 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY (Page No. - 32)
    2.1 RESEARCH DATA
           FIGURE 2 COMPANION DIAGNOSTICS MARKET: RESEARCH DESIGN METHODOLOGY
           2.1.1 SECONDARY DATA
                    2.1.1.1 Key data from secondary sources
           2.1.2 PRIMARY DATA
                    2.1.2.1 Primary sources
                    2.1.2.2 Key data from primary sources
                    2.1.2.3 Key industry insights
                               FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
    2.2 MARKET SIZE ESTIMATION
           2.2.1 BOTTOM-UP APPROACH
                    2.2.1.1 Approach 1: Company revenue estimation approach
                               FIGURE 4 MARKET: BOTTOM-UP APPROACH
                    2.2.1.2 Approach 2: Presentations of companies and primary interviews
                    2.2.1.3 Growth forecast (2021–2026)
                    2.2.1.4 CAGR projections
                               FIGURE 5 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
           2.2.2 TOP-DOWN APPROACH
                    FIGURE 6 MARKET: TOP-DOWN APPROACH
    2.3 MARKET BREAKDOWN & DATA TRIANGULATION
           FIGURE 7 DATA TRIANGULATION METHODOLOGY
    2.4 MARKET SHARE ANALYSIS
    2.5 ASSUMPTIONS FOR THE STUDY
    2.6 LIMITATIONS
    2.7 RISK ASSESSMENT
           2.7.1 RISK ASSESSMENT: MARKET
    2.8 GROWTH RATE ASSUMPTIONS
    2.9 COVID-19 HEALTH ASSESSMENT
    2.10 COVID-19 ECONOMIC ASSESSMENT
    2.11 ASSESSMENT OF IMPACT OF COVID-19 ON ECONOMIC SCENARIO
                    FIGURE 8 CRITERIA IMPACTING GLOBAL ECONOMY
                    FIGURE 9 RECOVERY SCENARIO OF GLOBAL ECONOMY
    2.12 ASSESSMENT OF IMPACT OF COVID-19 ON ECONOMIC SCENARIO IN MARKET

3 EXECUTIVE SUMMARY (Page No. - 48)
    FIGURE 10 COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021 VS. 2026 (USD MILLION)
    FIGURE 11 MARKET, BY TECHNOLOGY, 2021 VS. 2026 (USD MILLION)
    FIGURE 12 MARKET, BY INDICATION, 2021 VS. 2026 (USD MILLION)
    FIGURE 13 MARKET, BY END USER, 2021 VS. 2026 (USD MILLION)
    FIGURE 14 MARKET, BY REGION, 2021 VS. 2026 (USD MILLION)

4 PREMIUM INSIGHTS (Page No. - 52)
    4.1 MARKET OVERVIEW
           FIGURE 15 GROWING INCIDENCE OF CANCER TO DRIVE MARKET GROWTH
    4.2 MARKET SHARE, BY PRODUCT & SERVICE, 2021 VS. 2026
           FIGURE 16 ASSAYS, KITS & REAGENTS SEGMENT TO DOMINATE MARKET IN 2026
    4.3 MARKET SHARE, BY TECHNOLOGY, 2021 VS. 2026
           FIGURE 17 POLYMERASE CHAN REACTION SEGMENT TO LEAD MARKET DURING FORECAST PERIOD
    4.4 MARKET SHARE, BY INDICATION, 2021 VS. 2026
           FIGURE 18 CANCER SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD
    4.5 MARKET SHARE, BY END USER, 2021 VS. 2026
           FIGURE 19 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES SEGMENT TO LEAD MARKET IN 2026
    4.6 MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
           FIGURE 20 ASIA PACIFIC TO REGISTER HIGHEST GROWTH RATE IN MARKET DURING FORECAST PERIOD

5 MARKET OVERVIEW (Page No. - 56)
    5.1 INTRODUCTION
    5.2 MARKET DYNAMICS
           FIGURE 21 MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
           5.2.1 DRIVERS
                    5.2.1.1 Advantages of companion diagnostics
                               5.2.1.1.1 Growing need for targeted therapy
                               5.2.1.1.2 Rising importance of personalized medicine
                               FIGURE 22 GLOBAL LAUNCH OF PERSONALIZED MEDICINE PRODUCTS, 2008-2020
                               FIGURE 23 GROWTH IN US FDA PERSONALIZED MEDICINE APPROVAL RATE, 2015–2020
                               5.2.1.1.3 Increasing global incidence of cancer
                               FIGURE 24 GLOBAL CANCER INCIDENCE, 2008-2030
                               5.2.1.1.4 Growing application areas of companion diagnostics
           5.2.2 RESTRAINTS
                    5.2.2.1 High capital investment and low cost-benefit ratio
                    5.2.2.2 Expensive companion diagnostic tests
                    5.2.2.3 Uncertain reimbursement scenario in different regions
                               TABLE 1 COMPANION DIAGNOSTICS REIMBURSEMENT SCENARIO WORLDWIDE
                    5.2.2.4 High cost of immunotherapy treatment
                               TABLE 2 COST OF KEYTRUDA, BY REGION (2018)
           5.2.3 OPPORTUNITIES
                    5.2.3.1 Increasing demand for next-generation sequencing
                               TABLE 3 PARTNERSHIPS & COLLABORATIONS FOR DEVELOPING NGS-BASED COMPANION DIAGNOSTIC TESTS
                    5.2.3.2 Growing significance of companion diagnostics in drug development
                    5.2.3.3 Higher number of clinical trials
                               TABLE 4 LIST OF CLINICAL TRIALS FOR COMPANION DIAGNOSTICS
           5.2.4 CHALLENGES
                    5.2.4.1 Shortage of trained professionals
                    5.2.4.2 Lack of awareness of companion diagnostics testing
    5.3 IMPACT OF COVID-19 ON COMPANION DIAGNOSTICS MARKET
    5.4 PESSIMISTIC, OPTIMISTIC, AND REALISTIC SCENARIOS
           5.4.1 MARKET
                    FIGURE 25 PESSIMISTIC SCENARIO
                    FIGURE 26 OPTIMISTIC SCENARIO
                    FIGURE 27 REALISTIC SCENARIO
    5.5 PRICING ANALYSIS
           TABLE 5 PRICE OF COMPANION DIAGNOSTICS PRODUCT & SERVICE (2021)
    5.6 PATENT ANALYSIS
           FIGURE 28 PATENT ANALYSIS OF MARKET
    5.7 TRADE ANALYSIS
           5.7.1 TRADE ANALYSIS FOR COMPANION DIAGNOSTICS
                    TABLE 6 IMPORT DATA FOR COMPANION DIAGNOSTICS, BY COUNTRY, 2016–2020 (USD MILLION)
                    TABLE 7 EXPORT DATA FOR COMPANION DIAGNOSTICS, BY COUNTRY, 2016–2020 (USD MILLION)
    5.8 VALUE CHAIN ANALYSIS
           FIGURE 29 MAJOR VALUE IS ADDED DURING MANUFACTURING & ASSEMBLY PHASE
    5.9 SUPPLY CHAIN ANALYSIS
           FIGURE 30 MARKET: SUPPLY CHAIN ANALYSIS
    5.10 ECOSYSTEM ANALYSIS OF MARKET
           FIGURE 31 MARKET: ECOSYSTEM ANALYSIS
           5.10.1 ROLE IN ECOSYSTEM
    5.11 PORTER’S FIVE FORCES ANALYSIS
                    TABLE 8 MARKET: PORTER’S FIVE FORCES ANALYSIS
           5.11.1 THREAT OF NEW ENTRANTS
           5.11.2 THREAT OF SUBSTITUTES
           5.11.3 BARGAINING POWER OF BUYERS
           5.11.4 BARGAINING POWER OF SUPPLIERS
           5.11.5 DEGREE OF COMPETITION
    5.12 REGULATORY LANDSCAPE
           5.12.1 NORTH AMERICA
                    5.12.1.1 US
                    5.12.1.2 Canada
           5.12.2 EUROPE
           5.12.3 ASIA PACIFIC
                    5.12.3.1 China
                    5.12.3.2 Japan
                    5.12.3.3 India
           5.12.4 LATIN AMERICA
                    5.12.4.1 Brazil
                    5.12.4.2 Mexico
           5.12.5 MIDDLE EAST
    5.13 TECHNOLOGY ANALYSIS
    5.14 PESTLE ANALYSIS
    5.15 TRENDS/DISRUPTIONS IMPACTING THE BUSINESS OF CUSTOMERS
           5.15.1 REVENUE SOURCES ARE SHIFTING TOWARDS TECHNOLOGY-BASED SOLUTIONS DUE TO COVID-19 PANDEMIC
           5.15.2 REVENUE SHIFT FOR MARKET

6 COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE (Page No. - 82)
    6.1 INTRODUCTION
           TABLE 9 MARKET, BY PRODUCT & SERVICE, 2017–2020 (USD MILLION)
           TABLE 10 MARKET, BY PRODUCT & SERVICE, 2021–2026 (USD MILLION)
    6.2 ASSAYS, KITS & REAGENTS
           6.2.1 INCREASING VOLUME OF CDX TESTS PERFORMED IN LABORATORIES TO SUPPORT ADOPTION OF ASSAYS & KITS
           TABLE 11 KEY PRODUCTS IN ASSAYS AND KITS, BY COMPANY
           TABLE 12 COMPANION DIAGNOSTIC ASSAYS, KITS& REAGENTS MARKET, BY COUNTRY, 2017–2020 (USD MILLION)
           TABLE 13 COMPANION DIAGNOSTIC ASSAYS, KITS& REAGENTS MARKET, BY COUNTRY, 2021–2026 (USD MILLION)
    6.3 SOFTWARE & SERVICES
           6.3.1 NEED TO DELIVER ACCURATE AND TIMELY ANALYSIS OF DIAGNOSTICS TESTS TO SUPPORT MARKET GROWTH
                    TABLE 14 KEY PRODUCTS IN SOFTWARE & SERVICES, BY COMPANY
                    TABLE 15 COMPANION DIAGNOSTIC SOFTWARE & SERVICES MARKET, BY COUNTRY, 2017–2020 (USD MILLION)
                    TABLE 16 COMPANION DIAGNOSTIC SOFTWARE & SERVICES MARKET, BY COUNTRY, 2021–2026 (USD MILLION)

7 COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY (Page No. - 90)
    7.1 INTRODUCTION
           TABLE 17 MARKET, BY TECHNOLOGY, 2017–2020 (USD MILLION)
           TABLE 18 MARKET, BY TECHNOLOGY, 2021–2026 (USD MILLION)
    7.2 POLYMERASE CHAIN REACTION (PCR)
           7.2.1 GROWING APPLICATIONS IN PERSONALIZED MEDICINE AND COMPANION DIAGNOSTICS TO DRIVE GROWTH
                    TABLE 19 COMPARISON OF TISSUE SEQUENCING PLATFORMS FOR DETECTION OF RAS/BRAF MUTATION
                    TABLE 20 MAJOR PCR TESTS/KITS AVAILABLE
                    TABLE 21 MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2017–2020 (USD MILLION)
                    TABLE 22 MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2021–2026 (USD MILLION)
    7.3 NEXT-GENERATION SEQUENCING
           7.3.1 EXPECTED TO RECORD HIGHEST CAGR DURING FORECAST PERIOD
                    TABLE 23 MAJOR NGS TESTS/KITS AVAILABLE
                    TABLE 24 MARKET FOR NEXT-GENERATION SEQUENCING, BY COUNTRY, 2017–2020 (USD MILLION)
                    TABLE 25 MARKET FOR NEXT-GENERATION SEQUENCING, BY COUNTRY, 2021–2026 (USD MILLION)
    7.4 IN SITU HYBRIDIZATION
           7.4.1 INCREASING DEMAND IN SMALL-TUMOR DIAGNOSTICS TO DRIVE GROWTH
                    TABLE 26 MAJOR ISH TESTS/KITS AVAILABLE
                    TABLE 27 MARKET FOR IN SITU HYBRIDIZATION, BY COUNTRY, 2017–2020 (USD MILLION)
                    TABLE 28 MARKET FOR IN SITU HYBRIDIZATION, BY COUNTRY, 2021–2026 (USD MILLION)
    7.5 IMMUNOHISTOCHEMISTRY (IHC)
           7.5.1 INCREASING DEMAND FOR USER-FRIENDLY AND COST-EFFECTIVE TECHNOLOGIES TO SUPPORT GROWTH
                    TABLE 29 MAJOR IHC TESTS/KITS AVAILABLE
                    TABLE 30 MARKET FOR IMMUNOHISTOCHEMISTRY, BY COUNTRY, 2017–2020 (USD MILLION)
                    TABLE 31 MARKET FOR IMMUNOHISTOCHEMISTRY, BY COUNTRY, 2021–2026 (USD MILLION)
    7.6 OTHER TECHNOLOGIES
           TABLE 32 MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2017–2020 (USD MILLION)
           TABLE 33 MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2021–2026 (USD MILLION)

8 COMPANION DIAGNOSTICS MARKET, BY INDICATION (Page No. - 106)
    8.1 INTRODUCTION
           TABLE 34 MARKET, BY INDICATION, 2017–2020 (USD MILLION)
           TABLE 35 MARKET, BY INDICATION, 2021–2026 (USD MILLION)
    8.2 CANCER
           TABLE 36 MARKET FOR CANCER, BY TYPE, 2017–2020 (USD MILLION)
           TABLE 37 MARKET FOR CANCER, BY TYPE, 2021–2026 (USD MILLION)
           TABLE 38 MARKET FOR CANCER, BY COUNTRY, 2017–2020 (USD MILLION)
           TABLE 39 MARKET FOR CANCER, BY COUNTRY, 2021–2026 (USD MILLION)
           8.2.1 LUNG CANCER
                    8.2.1.1 Growing demand for effective therapeutic drugs to increase CDX adoption
                               FIGURE 32 GLOBAL LUNG CANCER INCIDENCE, 2012–2030
                               TABLE 40 MARKET FOR LUNG CANCER, BY COUNTRY, 2017–2020 (USD MILLION)
                               TABLE 41 MARKET FOR LUNG CANCER, BY COUNTRY, 2021–2026 (USD MILLION)
           8.2.2 BREAST CANCER
                    8.2.2.1 Wide prevalence of breast cancer among women contributes to large size of segment
                               TABLE 42 BREAST CANCER INCIDENCE, BY REGION, 2020 VS. 2030
                               TABLE 43 MARKET FOR BREAST CANCER, BY COUNTRY, 2017–2020 (USD MILLION)
                               TABLE 44 MARKET FOR BREAST CANCER, BY COUNTRY, 2021–2026 (USD MILLION)
           8.2.3 BLOOD CANCER
                    8.2.3.1 Increasing incidence of disease to boost market
                               TABLE 45 BLOOD CANCER INCIDENCE, BY REGION, 2020 VS. 2030
                               TABLE 46 MARKET FOR BLOOD CANCER, BY COUNTRY, 2017–2020 (USD MILLION)
                               TABLE 47 MARKET FOR BLOOD CANCER, BY COUNTRY, 2021–2026 (USD MILLION)
           8.2.4 COLORECTAL CANCER
                    8.2.4.1 Rising need for molecular profiling of primary tumors to drive segment growth
                               TABLE 48 MARKET FOR COLORECTAL CANCER, BY COUNTRY, 2017–2020 (USD MILLION)
                               TABLE 49 MARKET FOR COLORECTAL CANCER, BY COUNTRY, 2021–2026 (USD MILLION)
           8.2.5 OTHER CANCERS
                    TABLE 50 MARKET FOR OTHER CANCERS, BY COUNTRY, 2017–2020 (USD MILLION)
                    TABLE 51 MARKET FOR OTHER CANCERS, BY COUNTRY, 2021–2026 (USD MILLION)
    8.3 INFECTIOUS DISEASES
           8.3.1 INCREASING AWARENESS OF TARGETED THERAPIES TO PROPEL SEGMENT GROWTH
                    TABLE 52 MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2017–2020 (USD MILLION)
                    TABLE 53 MARKET FOR INFECTIOUS DIESEASES, BY COUNTRY, 2021–2026 (USD MILLION)
    8.4 CARDIOVASCULAR DISEASES
           8.4.1 RISING DEMAND FOR TARGETED THERAPIES TO DRIVE SEGMENT GROWTH
                    TABLE 54 MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2017–2020 (USD MILLION)
                    TABLE 55 MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2021–2026 (USD MILLION)
    8.5 NEUROLOGICAL DISEASES
           8.5.1 GROWING NUMBER OF ADVANCED TECHNOLOGIES TO BOOST ADOPTION OF COMPANION DIAGNOSTICS
                    TABLE 56 MARKET FOR NEUROLOGICAL DISEASES, BY COUNTRY, 2017–2020 (USD MILLION)
                    TABLE 57 MARKET FOR NEUROLOGICAL DISEASES, BY COUNTRY, 2021–2026 (USD MILLION)
    8.6 OTHER INDICATIONS
           TABLE 58 MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2017–2020 (USD MILLION)
           TABLE 59 MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2021–2026 (USD MILLION)

9 COMPANION DIAGNOSTICS MARKET, BY END USER (Page No. - 132)
    9.1 INTRODUCTION
           TABLE 60 MARKET, BY END USER, 2017–2020 (USD MILLION)
           TABLE 61 MARKET, BY END USER, 2021–2026 (USD MILLION)
    9.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
           9.2.1 INCREASING USE OF CDX IN PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES TO DRIVE MARKET GROWTH
                    TABLE 62 MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2017–2020 (USD MILLION)
                    TABLE 63 MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021–2026 (USD MILLION)
    9.3 REFERENCE LABORATORIES
           9.3.1 RISING DEMAND FOR TARGETED THERAPIES TO DRIVE GROWTH
                    TABLE 64 MARKET FOR REFERENCE LABORATORIES, BY COUNTRY, 2017–2020 (USD MILLION)
                    TABLE 65 MARKET FOR REFERENCE LABORATORIES, BY COUNTRY, 2021–2026 (USD MILLION)
    9.4 CONTRACT RESEARCH ORGANIZATIONS
           9.4.1 SIGNIFICANT DEMAND FOR COMPANION DIAGNOSTIC PRODUCTS FOR USE IN THERAPY-RELATED CLINICAL TRIALS
                    TABLE 66 MARKET FOR CRO, BY COUNTRY, 2017–2020 (USD MILLION)
                    TABLE 67 MARKET FOR CRO BY COUNTRY, 2021–2026 (USD MILLION)
    9.5 OTHER END USERS
           TABLE 68 MARKET FOR OTHER END USERS, BY COUNTRY, 2017–2020 (USD MILLION)
           TABLE 69 MARKET FOR OTHER END USERS, BY COUNTRY, 2021–2026 (USD MILLION)

10 COMPANION DIAGNOSTICS MARKET, BY REGION (Page No. - 142)
     10.1 INTRODUCTION
               TABLE 70 MARKET, BY REGION, 2017–2020 (USD MILLION)
               TABLE 71 MARKET, BY REGION, 2021–2026 (USD MILLION)
     10.2 NORTH AMERICA
               TABLE 72 NUMBER OF NEW CANCER CASES IN NORTH AMERICA IN 2020, BY TYPE OF CANCER
               FIGURE 33 NORTH AMERICA: CANCER INCIDENCE & MORTALITY, 2012–2035
               FIGURE 34 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET SNAPSHOT
               TABLE 73 NORTH AMERICA: MARKET, BY COUNTRY, 2017–2020 (USD MILLION)
               TABLE 74 NORTH AMERICA: MARKET, BY COUNTRY, 2021–2026 (USD MILLION)
               TABLE 75 NORTH AMERICA: MARKET, BY PRODUCT & SERVICE, 2017–2020 (USD MILLION)
               TABLE 76 NORTH AMERICA: MARKET, BY PRODUCT & SERVICE, 2021–2026 (USD MILLION)
               TABLE 77 NORTH AMERICA: MARKET, BY TECHNOLOGY, 2017–2020 (USD MILLION)
               TABLE 78 NORTH AMERICA: MARKET, BY TECHNOLOGY, 2021–2026 (USD MILLION)
               TABLE 79 NORTH AMERICA: MARKET, BY INDICATION, 2017–2020 (USD MILLION)
               TABLE 80 NORTH AMERICA: MARKET, BY INDICATION, 2021–2026 (USD MILLION)
               TABLE 81 NORTH AMERICA: MARKET FOR CANCER BY TYPE, 2017–2020 (USD MILLION)
               TABLE 82 NORTH AMERICA: MARKET FOR CANCER BY TYPE, 2021–2026 (USD MILLION)
               TABLE 83 NORTH AMERICA: MARKET, BY END USER, 2017–2020 (USD MILLION)
               TABLE 84 NORTH AMERICA: MARKET, BY END USER, 2021–2026 (USD MILLION)
             10.2.1 US
                       10.2.1.1 Increasing use of companion diagnostics for cancer treatment boosts market
                                   TABLE 85 US: CANCER INCIDENCE, BY TYPE OF CANCER, 2020 VS. 2040
                                   TABLE 86 US: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2017–2020 (USD MILLION)
                                   TABLE 87 US: MARKET, BY PRODUCT & SERVICE, 2021–2026 (USD MILLION)
                                   TABLE 88 US: MARKET, BY TECHNOLOGY, 2017–2020 (USD MILLION)
                                   TABLE 89 US: MARKET, BY TECHNOLOGY, 2021–2026 (USD MILLION)
                                   TABLE 90 US: MARKET, BY INDICATION, 2017–2020 (USD MILLION)
                                   TABLE 91 US: MARKET, BY INDICATION, 2021–2026 (USD MILLION)
                                   TABLE 92 US: MARKET FOR CANCER BY TYPE, 2017–2020 (USD MILLION)
                                   TABLE 93 US: MARKET FOR CANCER BY TYPE, 2021–2026 (USD MILLION)
                                   TABLE 94 US: MARKET, BY END USER, 2017–2020 (USD MILLION)
                                   TABLE 95 US: MARKET, BY END USER, 2021–2026 (USD MILLION)
             10.2.2 CANADA
                       10.2.2.1 Increasing government initiatives expected to drive market
                                   TABLE 96 CANADA: CANCER INCIDENCE, BY TYPE OF CANCER, 2020 VS. 2040
                                   TABLE 97 CANADA: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2017–2020 (USD MILLION)
                                   TABLE 98 CANADA: MARKET, BY PRODUCT & SERVICE, 2021–2026 (USD MILLION)
                                   TABLE 99 CANADA: MARKET, BY TECHNOLOGY, 2017–2020 (USD MILLION)
                                   TABLE 100 CANADA: MARKET, BY TECHNOLOGY, 2021–2026 (USD MILLION)
                                   TABLE 101 CANADA: MARKET, BY INDICATION, 2017–2020 (USD MILLION)
                                   TABLE 102 CANADA: MARKET, BY INDICATION, 2021–2026 (USD MILLION)
                                   TABLE 103 CANADA: MARKET FOR CANCER BY TYPE, 2017–2020 (USD MILLION)
                                   TABLE 104 CANADA: MARKET FOR CANCER BY TYPE, 2021–2026 (USD MILLION)
                                   TABLE 105 CANADA: MARKET, BY END USER, 2017–2020 (USD MILLION)
                                   TABLE 106 CANADA: MARKET, BY END USER, 2021–2026 (USD MILLION)
     10.3 EUROPE
               FIGURE 35 EUROPE: CANCER INCIDENCE & MORTALITY, 2012–2035
               TABLE 107 EUROPE: COMPANION DIAGNOSTICS MARKET, BY COUNTRY, 2017–2020 (USD MILLION)
               TABLE 108 EUROPE: MARKET, BY COUNTRY, 2021–2026 (USD MILLION)
               TABLE 109 EUROPE: MARKET, BY PRODUCT & SERVICE, 2017–2020 (USD MILLION)
               TABLE 110 EUROPE: MARKET, BY PRODUCT & SERVICE, 2021–2026 (USD MILLION)
               TABLE 111 EUROPE: MARKET, BY TECHNOLOGY, 2017–2020 (USD MILLION)
               TABLE 112 EUROPE: MARKET, BY TECHNOLOGY, 2021–2026 (USD MILLION)
               TABLE 113 EUROPE: MARKET, BY INDICATION, 2017–2020 (USD MILLION)
               TABLE 114 EUROPE: MARKET, BY INDICATION, 2021–2026 (USD MILLION)
               TABLE 115 EUROPE: MARKET FOR CANCER BY TYPE, 2017–2020 (USD MILLION)
               TABLE 116 EUROPE: MARKET FOR CANCER BY TYPE, 2021–2026 (USD MILLION)
               TABLE 117 EUROPE: MARKET, BY END USER, 2017–2020 (USD MILLION)
               TABLE 118 EUROPE: MARKET, BY END USER, 2021–2026 (USD MILLION)
             10.3.1 GERMANY
                       10.3.1.1 Favorable government policies to drive market
                                   TABLE 119 GERMANY: CANCER INCIDENCE, BY TYPE OF CANCER, 2020 VS. 2040
                                   TABLE 120 GERMANY: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2017–2020 (USD MILLION)
                                   TABLE 121 GERMANY: MARKET, BY PRODUCT & SERVICE, 2021–2026 (USD MILLION)
                                   TABLE 122 GERMANY: MARKET, BY TECHNOLOGY, 2017–2020 (USD MILLION)
                                   TABLE 123 GERMANY: MARKET, BY TECHNOLOGY, 2021–2026 (USD MILLION)
                                   TABLE 124 GERMANY: MARKET, BY INDICATION, 2017–2020 (USD MILLION)
                                   TABLE 125 GERMANY: MARKET, BY INDICATION, 2021–2026 (USD MILLION)
                                   TABLE 126 GERMANY: MARKET FOR CANCER BY TYPE, 2017–2020 (USD MILLION)
                                   TABLE 127 GERMANY: MARKET FOR CANCER BY TYPE, 2021–2026 (USD MILLION)
                                   TABLE 128 GERMANY: MARKET, BY END USER, 2017–2020 (USD MILLION)
                                   TABLE 129 GERMANY: MARKET, BY END USER, 2021–2026 (USD MILLION)
             10.3.2 UK
                       10.3.2.1 Growing life science industry and increasing focus on research to propel market
                                   TABLE 130 UK: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2017–2020 (USD MILLION)
                                   TABLE 131 UK: MARKET, BY PRODUCT & SERVICE, 2021–2026 (USD MILLION)
                                   TABLE 132 UK: MARKET, BY TECHNOLOGY, 2017–2020 (USD MILLION)
                                   TABLE 133 UK: MARKET, BY TECHNOLOGY, 2021–2026 (USD MILLION)
                                   TABLE 134 UK: MARKET, BY INDICATION, 2017–2020 (USD MILLION)
                                   TABLE 135 UK: MARKET, BY INDICATION, 2021–2026 (USD MILLION)
                                   TABLE 136 UK: MARKET FOR CANCER BY TYPE, 2017–2020 (USD MILLION)
                                   TABLE 137 UK: MARKET FOR CANCER BY TYPE, 2021–2026 (USD MILLION)
                                   TABLE 138 UK: MARKET, BY END USER, 2017–2020 (USD MILLION)
                                   TABLE 139 UK: MARKET, BY END USER, 2021–2026 (USD MILLION)
             10.3.3 SWITZERLAND
                       10.3.3.1 Strong research-oriented pharma industry supports market growth
                                   TABLE 140 SWITZERLAND: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2017–2020 (USD MILLION)
                                   TABLE 141 SWITZERLAND: MARKET, BY PRODUCT & SERVICE, 2021–2026 (USD MILLION)
                                   TABLE 142 SWITZERLAND: MARKET, BY TECHNOLOGY, 2017–2020 (USD MILLION)
                                   TABLE 143 SWITZERLAND: MARKET, BY TECHNOLOGY, 2021–2026 (USD MILLION)
                                   TABLE 144 SWITZERLAND: MARKET, BY INDICATION, 2017–2020 (USD MILLION)
                                   TABLE 145 SWITZERLAND: MARKET, BY INDICATION, 2021–2026 (USD MILLION)
                                   TABLE 146 SWITZERLAND: MARKET FOR CANCER BY TYPE, 2017–2020 (USD MILLION)
                                   TABLE 147 SWITZERLAND: MARKET FOR CANCER BY TYPE, 2021–2026 (USD MILLION)
                                   TABLE 148 SWITZERLAND: MARKET, BY END USER, 2017–2020 (USD MILLION)
                                   TABLE 149 SWITZERLAND: MARKET, BY END USER, 2021–2026 (USD MILLION)
             10.3.4 FRANCE
                       10.3.4.1 Increasing government funding for research to support market growth
                                   TABLE 150 FRANCE: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2017–2020 (USD MILLION)
                                   TABLE 151 FRANCE: MARKET, BY PRODUCT & SERVICE, 2021–2026 (USD MILLION)
                                   TABLE 152 FRANCE: MARKET, BY TECHNOLOGY, 2017–2020 (USD MILLION)
                                   TABLE 153 FRANCE: MARKET, BY TECHNOLOGY, 2021–2026 (USD MILLION)
                                   TABLE 154 FRANCE: MARKET, BY INDICATION, 2017–2020 (USD MILLION)
                                   TABLE 155 FRANCE: MARKET, BY INDICATION, 2021–2026 (USD MILLION)
                                   TABLE 156 FRANCE: MARKET FOR CANCER BY TYPE, 2017–2020 (USD MILLION)
                                   TABLE 157 FRANCE: MARKET FOR CANCER BY TYPE, 2021–2026 (USD MILLION)
                                   TABLE 158 FRANCE: MARKET, BY END USER, 2017–2020 (USD MILLION)
                                   TABLE 159 FRANCE: MARKET, BY END USER, 2021–2026 (USD MILLION)
             10.3.5 ITALY
                       10.3.5.1 Growing demand for better and more powerful therapeutics
                                   TABLE 160 ITALY: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2017–2020 (USD MILLION)
                                   TABLE 161 ITALY: MARKET, BY PRODUCT & SERVICE, 2021–2026 (USD MILLION)
                                   TABLE 162 ITALY: MARKET, BY TECHNOLOGY, 2017–2020 (USD MILLION)
                                   TABLE 163 ITALY: MARKET, BY TECHNOLOGY, 2021–2026 (USD MILLION)
                                   TABLE 164 ITALY: MARKET, BY INDICATION, 2017–2020 (USD MILLION)
                                   TABLE 165 ITALY: MARKET, BY INDICATION, 2021–2026 (USD MILLION)
                                   TABLE 166 ITALY: MARKET FOR CANCER BY TYPE, 2017–2020 (USD MILLION)
                                   TABLE 167 ITALY: MARKET FOR CANCER BY TYPE, 2021–2026 (USD MILLION)
                                   TABLE 168 ITALY: MARKET, BY END USER, 2017–2020 (USD MILLION)
                                   TABLE 169 ITALY: MARKET, BY END USER, 2021–2026 (USD MILLION)
             10.3.6 SPAIN
                       10.3.6.1 Increasing focus on advancement of personalized medicine to drive market growth
                                   TABLE 170 SPAIN: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2017–2020 (USD MILLION)
                                   TABLE 171 SPAIN: MARKET, BY PRODUCT & SERVICE, 2021–2026 (USD MILLION)
                                   TABLE 172 SPAIN: MARKET, BY TECHNOLOGY, 2017–2020 (USD MILLION)
                                   TABLE 173 SPAIN: MARKET, BY TECHNOLOGY, 2021–2026 (USD MILLION)
                                   TABLE 174 SPAIN: MARKET, BY INDICATION, 2017–2020 (USD MILLION)
                                   TABLE 175 SPAIN: MARKET, BY INDICATION, 2021–2026 (USD MILLION)
                                   TABLE 176 SPAIN: MARKET FOR CANCER BY TYPE, 2017–2020 (USD MILLION)
                                   TABLE 177 SPAIN: MARKET FOR CANCER BY TYPE, 2021–2026 (USD MILLION)
                                   TABLE 178 SPAIN: MARKET, BY END USER, 2017–2020 (USD MILLION)
                                   TABLE 179 SPAIN: MARKET, BY END USER, 2021–2026 (USD MILLION)
             10.3.7 REST OF EUROPE
                       TABLE 180 ROE: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2017–2020 (USD MILLION)
                       TABLE 181 ROE: MARKET, BY PRODUCT & SERVICE, 2021–2026 (USD MILLION)
                       TABLE 182 ROE: MARKET, BY TECHNOLOGY, 2017–2020 (USD MILLION)
                       TABLE 183 ROE: MARKET, BY TECHNOLOGY, 2021–2026 (USD MILLION)
                       TABLE 184 ROE: MARKET, BY INDICATION, 2017–2020 (USD MILLION)
                       TABLE 185 ROE: MARKET, BY INDICATION, 2021–2026 (USD MILLION)
                       TABLE 186 ROE: MARKET FOR CANCER BY TYPE, 2017–2020 (USD MILLION)
                       TABLE 187 ROE: MARKET FOR CANCER BY TYPE, 2021–2026 (USD MILLION)
                       TABLE 188 ROE: MARKET, BY END USER, 2017–2020 (USD MILLION)
                       TABLE 189 ROE: MARKET, BY END USER, 2021–2026 (USD MILLION)
     10.4 ASIA PACIFIC
               FIGURE 36 ASIA PACIFIC: CANCER INCIDENCE & MORTALITY, 2012–2035
               FIGURE 37 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET SNAPSHOT
               TABLE 190 ASIA PACIFIC: MARKET, BY COUNTRY, 2017–2020 (USD MILLION)
               TABLE 191 ASIA PACIFIC: MARKET, BY COUNTRY, 2021–2026 (USD MILLION)
               TABLE 192 ASIA PACIFIC: MARKET, BY PRODUCT & SERVICE, 2017–2020 (USD MILLION)
               TABLE 193 ASIA PACIFIC: MARKET, BY PRODUCT & SERVICE, 2021–2026 (USD MILLION)
               TABLE 194 ASIA PACIFIC: MARKET, BY TECHNOLOGY, 2017–2020 (USD MILLION)
               TABLE 195 ASIA PACIFIC: MARKET, BY TECHNOLOGY, 2021–2026 (USD MILLION)
               TABLE 196 ASIA PACIFIC: MARKET, BY INDICATION, 2017–2020 (USD MILLION)
               TABLE 197 ASIA PACIFIC: MARKET, BY INDICATION, 2021–2026 (USD MILLION)
               TABLE 198 ASIA PACIFIC: MARKET FOR CANCER BY TYPE, 2017–2020 (USD MILLION)
               TABLE 199 ASIA PACIFIC: MARKET FOR CANCER BY TYPE, 2021–2026 (USD MILLION)
               TABLE 200 ASIA PACIFIC: MARKET, BY END USER, 2017–2020 (USD MILLION)
               TABLE 201 ASIA PACIFIC: MARKET, BY END USER, 2021–2026 (USD MILLION)
             10.4.1 CHINA
                       10.4.1.1 Growing public access to advanced healthcare facilities to drive market
                                   TABLE 202 CHINA: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2017–2020 (USD MILLION)
                                   TABLE 203 CHINA: MARKET, BY PRODUCT & SERVICE, 2021–2026 (USD MILLION)
                                   TABLE 204 CHINA: MARKET, BY TECHNOLOGY, 2017–2020 (USD MILLION)
                                   TABLE 205 CHINA: MARKET, BY TECHNOLOGY, 2021–2026 (USD MILLION)
                                   TABLE 206 CHINA: MARKET, BY INDICATION, 2017–2020 (USD MILLION)
                                   TABLE 207 CHINA: MARKET, BY INDICATION, 2021–2026 (USD MILLION)
                                   TABLE 208 CHINA: MARKET FOR CANCER BY TYPE, 2017–2020 (USD MILLION)
                                   TABLE 209 CHINA: MARKET FOR CANCER BY TYPE, 2021–2026 (USD MILLION)
                                   TABLE 210 CHINA: MARKET, BY END USER, 2017–2020 (USD MILLION)
                                   TABLE 211 CHINA: MARKET, BY END USER, 2021–2026 (USD MILLION)
             10.4.2 JAPAN
                       10.4.2.1 Research initiatives supporting market growth
                                   TABLE 212 JAPAN: CANCER INCIDENCE, BY TYPE OF CANCER, 2020 VS. 2040
                                   TABLE 213 JAPAN: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2017–2020 (USD MILLION)
                                   TABLE 214 JAPAN: MARKET, BY PRODUCT & SERVICE, 2021–2026 (USD MILLION)
                                   TABLE 215 JAPAN: MARKET, BY TECHNOLOGY, 2017–2020 (USD MILLION)
                                   TABLE 216 JAPAN: MARKET, BY TECHNOLOGY, 2021–2026 (USD MILLION)
                                   TABLE 217 JAPAN: MARKET, BY INDICATION, 2017–2020 (USD MILLION)
                                   TABLE 218 JAPAN: MARKET, BY INDICATION, 2021–2026 (USD MILLION)
                                   TABLE 219 JAPAN: MARKET FOR CANCER BY TYPE, 2017–2020 (USD MILLION)
                                   TABLE 220 JAPAN: MARKET FOR CANCER BY TYPE, 2021–2026 (USD MILLION)
                                   TABLE 221 JAPAN: MARKET, BY END USER, 2017–2020 (USD MILLION)
                                   TABLE 222 JAPAN: MARKET, BY END USER, 2021–2026 (USD MILLION)
             10.4.3 INDIA
                       10.4.3.1 Increased demand for early cancer diagnosis to support market growth
                                   TABLE 223 INDIA: CANCER INCIDENCE, BY TYPE OF CANCER, 2020 VS. 2040
                                   TABLE 224 INDIA: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2017–2020 (USD MILLION)
                                   TABLE 225 INDIA: MARKET, BY PRODUCT & SERVICE, 2021–2026 (USD MILLION)
                                   TABLE 226 INDIA: MARKET, BY TECHNOLOGY, 2017–2020 (USD MILLION)
                                   TABLE 227 INDIA: MARKET, BY TECHNOLOGY, 2021–2026 (USD MILLION)
                                   TABLE 228 INDIA: MARKET, BY INDICATION, 2017–2020 (USD MILLION)
                                   TABLE 229 INDIA: MARKET, BY INDICATION, 2021–2026 (USD MILLION)
                                   TABLE 230 INDIA: MARKET FOR CANCER BY TYPE, 2017–2020 (USD MILLION)
                                   TABLE 231 INDIA: MARKET FOR CANCER BY TYPE, 2021–2026 (USD MILLION)
                                   TABLE 232 INDIA: MARKET, BY END USER, 2017–2020 (USD MILLION)
                                   TABLE 233 INDIA: MARKET, BY END USER, 2021–2026 (USD MILLION)
             10.4.4 AUSTRALIA
                       10.4.4.1 Initiatives to enhance healthcare access and infrastructure for aging population to drive market
                                   TABLE 234 AUSTRALIA: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2017–2020 (USD MILLION)
                                   TABLE 235 AUSTRALIA: MARKET, BY PRODUCT & SERVICE, 2021–2026 (USD MILLION)
                                   TABLE 236 AUSTRALIA: MARKET, BY TECHNOLOGY, 2017–2020 (USD MILLION)
                                   TABLE 237 AUSTRALIA: MARKET, BY TECHNOLOGY, 2021–2026 (USD MILLION)
                                   TABLE 238 AUSTRALIA: MARKET, BY INDICATION, 2017–2020 (USD MILLION)
                                   TABLE 239 AUSTRALIA: MARKET, BY INDICATION, 2021–2026 (USD MILLION)
                                   TABLE 240 AUSTRALIA: MARKET FOR CANCER BY TYPE, 2017–2020 (USD MILLION)
                                   TABLE 241 AUSTRALIA: MARKET FOR CANCER BY TYPE, 2021–2026 (USD MILLION)
                                   TABLE 242 AUSTRALIA: MARKET, BY END USER, 2017–2020 (USD MILLION)
                                   TABLE 243 AUSTRALIA: MARKET, BY END USER, 2021–2026 (USD MILLION)
             10.4.5 REST OF ASIA PACIFIC
                       TABLE 244 ROAPAC: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2017–2020 (USD MILLION)
                       TABLE 245 ROAPAC: MARKET, BY PRODUCT & SERVICE, 2021–2026 (USD MILLION)
                       TABLE 246 ROAPAC: MARKET, BY TECHNOLOGY, 2017–2020 (USD MILLION)
                       TABLE 247 ROAPAC: MARKET, BY TECHNOLOGY, 2021–2026 (USD MILLION)
                       TABLE 248 ROAPAC: MARKET, BY INDICATION, 2017–2020 (USD MILLION)
                       TABLE 249 ROAPAC: MARKET, BY INDICATION, 2021–2026 (USD MILLION)
                       TABLE 250 ROAPAC: MARKET FOR CANCER BY TYPE, 2017–2020 (USD MILLION)
                       TABLE 251 ROAPAC: MARKET FOR CANCER BY TYPE, 2021–2026 (USD MILLION)
                       TABLE 252 ROAPAC: MARKET, BY END USER, 2017–2020 (USD MILLION)
                       TABLE 253 ROAPAC: MARKET, BY END USER, 2021–2026 (USD MILLION)
     10.5 LATIN AMERICA
               TABLE 254 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET, BY COUNTRY, 2017–2020 (USD MILLION)
               TABLE 255 LATIN AMERICA: MARKET, BY COUNTRY, 2021–2026 (USD MILLION)
               TABLE 256 LATIN AMERICA: MARKET, BY PRODUCT & SERVICE, 2017–2020 (USD MILLION)
               TABLE 257 LATIN AMERICA: MARKET, BY PRODUCT & SERVICE, 2021–2026 (USD MILLION)
               TABLE 258 LATIN AMERICA: MARKET, BY TECHNOLOGY, 2017–2020 (USD MILLION)
               TABLE 259 LATIN AMERICA: MARKET, BY TECHNOLOGY, 2021–2026 (USD MILLION)
               TABLE 260 LATIN AMERICA: MARKET, BY INDICATION, 2017–2020 (USD MILLION)
               TABLE 261 LATIN AMERICA: MARKET, BY INDICATION, 2021–2026 (USD MILLION)
               TABLE 262 LATIN AMERICA: MARKET FOR CANCER BY TYPE, 2017–2020 (USD MILLION)
               TABLE 263 LATIN AMERICA: MARKET FOR CANCER BY TYPE, 2021–2026 (USD MILLION)
               TABLE 264 LATIN AMERICA: MARKET, BY END USER, 2017–2020 (USD MILLION)
               TABLE 265 LATIN AMERICA: MARKET, BY END USER, 2021–2026 (USD MILLION)
             10.5.1 BRAZIL
                       10.5.1.1 Increasing incidence of lifestyle diseases drives market
                                   TABLE 266 BRAZIL: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2017–2020 (USD MILLION)
                                   TABLE 267 BRAZIL: MARKET, BY PRODUCT & SERVICE, 2021–2026 (USD MILLION)
                                   TABLE 268 BRAZIL: MARKET, BY TECHNOLOGY, 2017–2020 (USD MILLION)
                                   TABLE 269 BRAZIL: MARKET, BY TECHNOLOGY, 2021–2026 (USD MILLION)
                                   TABLE 270 BRAZIL: MARKET, BY INDICATION, 2017–2020 (USD MILLION)
                                   TABLE 271 BRAZIL: MARKET, BY INDICATION, 2021–2026 (USD MILLION)
                                   TABLE 272 BRAZIL: MARKET FOR CANCER BY TYPE, 2017–2020 (USD MILLION)
                                   TABLE 273 BRAZIL: MARKET FOR CANCER BY TYPE, 2021–2026 (USD MILLION)
                                   TABLE 274 BRAZIL: MARKET, BY END USER, 2017–2020 (USD MILLION)
                                   TABLE 275 BRAZIL: MARKET, BY END USER, 2021–2026 (USD MILLION)
             10.5.2 MEXICO
                       10.5.2.1 Growing medical tourism to fuel demand for companion diagnostics
                                   TABLE 276 MEXICO: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2017–2020 (USD MILLION)
                                   TABLE 277 MEXICO: MARKET, BY PRODUCT & SERVICE, 2021–2026 (USD MILLION)
                                   TABLE 278 MEXICO: MARKET, BY TECHNOLOGY, 2017–2020 (USD MILLION)
                                   TABLE 279 MEXICO: MARKET, BY TECHNOLOGY, 2021–2026 (USD MILLION)
                                   TABLE 280 MEXICO: MARKET, BY INDICATION, 2017–2020 (USD MILLION)
                                   TABLE 281 MEXICO: MARKET, BY INDICATION, 2021–2026 (USD MILLION)
                                   TABLE 282 MEXICO: MARKET FOR CANCER BY TYPE, 2017–2020 (USD MILLION)
                                   TABLE 283 MEXICO: MARKET FOR CANCER BY TYPE, 2021–2026 (USD MILLION)
                                   TABLE 284 MEXICO: MARKET, BY END USER, 2017–2020 (USD MILLION)
                                   TABLE 285 MEXICO: MARKET, BY END USER, 2021–2026 (USD MILLION)
             10.5.3 REST OF LATIN AMERICA
                       TABLE 286 ROLATAM: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2017–2020 (USD MILLION)
                       TABLE 287 ROLATAM: MARKET, BY PRODUCT & SERVICE, 2021–2026 (USD MILLION)
                       TABLE 288 ROLATAM: MARKET, BY TECHNOLOGY, 2017–2020 (USD MILLION)
                       TABLE 289 ROLATAM: MARKET, BY TECHNOLOGY, 2021–2026 (USD MILLION)
                       TABLE 290 ROLATAM: MARKET, BY INDICATION, 2017–2020 (USD MILLION)
                       TABLE 291 ROLATAM: MARKET, BY INDICATION, 2021–2026 (USD MILLION)
                       TABLE 292 ROLATAM: MARKET FOR CANCER BY TYPE, 2017–2020 (USD MILLION)
                       TABLE 293 ROLATAM: MARKET FOR CANCER BY TYPE, 2021–2026 (USD MILLION)
                       TABLE 294 ROLATAM: MARKET, BY END USER, 2017–2020 (USD MILLION)
                       TABLE 295 ROLATAM: MARKET, BY END USER, 2021–2026 (USD MILLION)
     10.6 MIDDLE EAST & AFRICA
             10.6.1 INCREASING FOCUS ON PRECISION MEDICINE TO DRIVE MARKET GROWTH
                       TABLE 296 MIDDLE EAST & AFRICA: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2017–2020 (USD MILLION)
                       TABLE 297 MIDDLE EAST & AFRICA: MARKET, BY PRODUCT & SERVICE, 2021–2026 (USD MILLION)
                       TABLE 298 MIDDLE EAST & AFRICA: MARKET, BY TECHNOLOGY, 2017–2020 (USD MILLION)
                       TABLE 299 MIDDLE EAST & AFRICA: MARKET, BY TECHNOLOGY, 2021–2026 (USD MILLION)
                       TABLE 300 MIDDLE EAST & AFRICA: MARKET, BY INDICATION, 2017–2020 (USD MILLION)
                       TABLE 301 MIDDLE EAST & AFRICA: MARKET, BY INDICATION, 2021–2026 (USD MILLION)
                       TABLE 302 MIDDLE EAST & AFRICA: MARKET FOR CANCER BY TYPE, 2017–2020 (USD MILLION)
                       TABLE 303 MIDDLE EAST & AFRICA: MARKET FOR CANCER BY TYPE, 2021–2026 (USD MILLION)
                       TABLE 304 MIDDLE EAST & AFRICA: MARKET, BY END USER, 2017–2020 (USD MILLION)
                       TABLE 305 MIDDLE EAST & AFRICA: MARKET, BY END USER, 2021–2026 (USD MILLION)

11 COMPETITIVE LANDSCAPE (Page No. - 270)
     11.1 OVERVIEW
     11.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
             11.2.1 OVERVIEW OF STRATEGIES DEPLOYED BY PLAYERS IN COMPANION DIAGNOSTICS MARKET
                       TABLE 306 OVERVIEW OF STRATEGIES DEPLOYED BY KEY COMPANION DIAGNOSTICS MANUFACTURING COMPANIES
     11.3 REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS
               FIGURE 38 REVENUE SHARE ANALYSIS OF TOP PLAYERS IN MARKET (2015-2020)
     11.4 MARKET SHARE ANALYSIS
               FIGURE 39 MARKET SHARE, BY KEY PLAYER (2020)
               TABLE 307 COMPANION DIAGNOSTICSMARKET: DEGREE OF COMPETITION
     11.5 COMPANY EVALUATION QUADRANT
             11.5.1 LIST OF EVALUATED VENDORS
             11.5.2 STARS
             11.5.3 EMERGING LEADERS
             11.5.4 PERVASIVE PLAYERS
             11.5.5 PARTICIPANTS
                       FIGURE 40 COMPANION DIAGNOSTICS MARKET: COMPETITIVE LEADERSHIP MAPPING, 2020
     11.6 COMPETITIVE LEADERSHIP MAPPING FOR STARTUPS/SMES (2020)
             11.6.1 PROGRESSIVE COMPANIES
             11.6.2 STARTING BLOCKS
             11.6.3 RESPONSIVE COMPANIES
             11.6.4 DYNAMIC COMPANIES
                       FIGURE 41 COMPANION DIAGNOSTICSMARKET: COMPETITIVE LEADERSHIP MAPPING FOR STARTUPS/SMES, 2020
     11.7 COMPETITIVE BENCHMARKING
             11.7.1 PRODUCT AND GEOGRAPHIC FOOTPRINT ANALYSIS
                       FIGURE 42 PRODUCT AND GEOGRAPHIC FOOTPRINT ANALYSIS OF TOP PLAYERS IN COMPANION DIAGNOSTICSMARKET
                       TABLE 308 PRODUCT FOOTPRINT OF COMPANIES
                       TABLE 309 REGIONAL FOOTPRINT OF COMPANIES
     11.8 COMPETITIVE SCENARIO
             11.8.1 PRODUCT LAUNCHES & REGULATORY APPROVALS
                       TABLE 310 KEY PRODUCT LAUNCHES
             11.8.2 DEALS
                       TABLE 311 KEY DEALS

12 COMPANY PROFILES (Page No. - 281)
(Business overview, Products offered, Recent developments & MnM View)*
     12.1 KEY PLAYERS
             12.1.1 F. HOFFMANN-LA ROCHE AG
                       TABLE 312 F. HOFFMANN-LA ROCHE AG: BUSINESS OVERVIEW
                       FIGURE 43 F. HOFFMANN-LA ROCHE AG: COMPANY SNAPSHOT (2020)
             12.1.2 AGILENT TECHNOLOGIES, INC.
                       TABLE 313 AGILENT TECHNOLOGIES, INC.: BUSINESS OVERVIEW
                       FIGURE 44 AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2020)
             12.1.3 QIAGEN
                       TABLE 314 QIAGEN: BUSINESS OVERVIEW
                       FIGURE 45 QIAGEN: COMPANY SNAPSHOT (2020)
             12.1.4 THERMO FISHER SCIENTIFIC, INC.
                       TABLE 315 THERMO FISHER SCIENTIFIC, INC.: BUSINESS OVERVIEW
                       FIGURE 46 THERMO FISHER SCIENTIFIC, INC.: COMPANY SNAPSHOT (2020)
             12.1.5 ABBOTT LABORATORIES, INC.
                       TABLE 316 ABBOTT LABORATORIES, INC.: BUSINESS OVERVIEW
                       FIGURE 47 ABBOTT LABORATORIES, INC.: COMPANY SNAPSHOT (2020)
             12.1.6 ALMAC GROUP
                       TABLE 317 ALMAC GROUP: BUSINESS OVERVIEW
             12.1.7 DANAHER CORPORATION
                       TABLE 318 DANAHER CORPORATION: BUSINESS OVERVIEW
                       FIGURE 48 DANAHER CORPORATION: COMPANY SNAPSHOT (2020)
             12.1.8 ILLUMINA, INC.
                       TABLE 319 ILLUMINA, INC.: BUSINESS OVERVIEW
                       FIGURE 49 ILLUMINA, INC.: COMPANY SNAPSHOT (2020)
             12.1.9 BIOMÉRIEUX SA
                       TABLE 320 BIOMÉRIEUX SA: BUSINESS OVERVIEW
                       FIGURE 50 BIOMÉRIEUX SA: COMPANY SNAPSHOT (2020)
             12.1.10 MYRIAD GENETICS, INC.
                       TABLE 321 MYRIAD GENETICS, INC.: BUSINESS OVERVIEW
                       FIGURE 51 MYRIAD GENETICS, INC.: COMPANY SNAPSHOT (2020)
             12.1.11 SYSMEX CORPORATION
                       TABLE 322 SYSMEX CORPORATION: BUSINESS OVERVIEW
                       FIGURE 52 SYSMEX CORPORATION: COMPANY SNAPSHOT (2020)
*Details on Business overview, Products offered, Recent developments & MnM View might not be captured in case of unlisted companies.
     12.2 OTHER PLAYERS
             12.2.1 ABNOVA CORPORATION
             12.2.2 GUARDANT HEALTH, INC.
             12.2.3 ICON PLC
             12.2.4 BIOGENEX LABORATORIES, INC.
             12.2.5 INVIVOSCRIBE TECHNOLOGIES
             12.2.6 ARCHERDX, INC.
             12.2.7 NG BIOTECH
             12.2.8 Q² SOLUTIONS
             12.2.9 AMOY DIAGNOSTICS CO., LTD.
             12.2.10 ABACUS DIAGNOSTICA OY
             12.2.11 ASURAGEN INC.
             12.2.12 SAGA DIAGNOSTICS
             12.2.13 MESO SCALE DIAGNOSTICS, LLC.
             12.2.14 CREATIVE BIOLABS

13 APPENDIX (Page No. - 323)
     13.1 DISCUSSION GUIDE
     13.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
     13.3 AVAILABLE CUSTOMIZATIONS
     13.4 RELATED REPORTS
     13.5 AUTHOR DETAILS

This study involved four major activities in estimating the current size of the companion diagnostics market. Exhaustive secondary research was carried out to collect information on the market, its peer markets, and its parent market. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size. After that, market breakdown and data triangulation procedures were used to estimate segments and subsegments' market size.

Secondary Research

In the secondary research process, various secondary sources such as annual reports, press releases & investor presentations of companies, white papers, certified publications, articles by recognized authors, gold-standard & silver-standard websites, regulatory bodies, and databases (such as D&B Hoovers, Bloomberg Business, and Factiva) were referred to identify and collect information for this study.

Primary Research

In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. Primary sources were mainly industry experts from the core and related industries and preferred suppliers, manufacturers, distributors, service providers, technology developers, researchers, and organizations related to all segments of this industry’s value chain. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts, C-level executives of key market players, and industry consultants, to obtain and verify the critical qualitative and quantitative information as well as assess future prospects.

The following is a breakdown of the primary respondents:

Companion Diagnostics Market Size

To know about the assumptions considered for the study, download the pdf brochure

Market Size Estimation

Both top-down and bottom-up approaches were used to estimate and validate the companion diagnostics market's total size. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

  • The key players in the industry have been identified through extensive secondary research
  • The revenues generated by leading players operating in the companion diagnostics market have been determined through primary and secondary research
  • All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources

Market Size: Top-Down Approach

Companion Diagnostics Market Size, and Share

To know about the assumptions considered for the study, Request for Free Sample Report

Data Triangulation

After arriving at the overall market size applying the process mentioned above, the total market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.

Report Objectives

  • To define, describe, segment, and forecast the global companion diagnostics market by product & service, technology, indication, end user, and region
  • To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
  • To analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall companion diagnostics market
  • To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
  • To forecast the size of the market segments with respect to five regions, namely, North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa
  • To profile the key players and comprehensively analyze their product portfolios, market positions, and core competencies
  • To track and analyze company developments such as product launches, agreements, partnerships, and acquisitions in the companion diagnostics market
  • To benchmark players within the market using the proprietary "Competitive Leadership Mapping" framework, which analyzes market players on various parameters within the broad categories of business and product strategy

Available Customizations

With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for this report:

Country Information

  • Companion diagnostics market size and growth rate estimates for countries in the Rest of Europe, the Rest of Asia Pacific, Latin America, and Middle East & Africa

Company Profiles

  • Additional five company profiles of players operating in the companion diagnostics market.
Custom Market Research Services

We will customize the research for you, in case the report listed above does not meet with your exact requirements. Our custom research will comprehensively cover the business information you require to help you arrive at strategic and profitable business decisions.

Request Customization

Instant Answers with GPT - Ask Now!

Ask real questions. Get complete answers !
Report Code
MD 5463
Published ON
Feb, 2022
Choose License Type
BUY NOW
  • SHARE
X
Request Customization
Speak to Analyst
Speak to Analyst
OR FACE-TO-FACE MEETING
PERSONALIZE THIS RESEARCH
  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
REQUEST A FREE CUSTOMIZATION
LET US HELP YOU!
  • What are the Known and Unknown Adjacencies Impacting the Companion Diagnostics Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
CUSTOMIZED WORKSHOP REQUEST
+1-888-600-6441
  • Call Us
  • +1-888-600-6441 (Corporate office hours)
  • +1-888-600-6441 (US/Can toll free)
  • +44-800-368-9399 (UK office hours)
CONNECT WITH US
ABOUT TRUST ONLINE
©2024 MarketsandMarkets Research Private Ltd. All rights reserved
DMCA.com Protection Status Website Feedback